Tags

Type your tag names separated by a space and hit enter

Blackcurrant seed oil for prevention of atopic dermatitis in newborns: a randomized, double-blind, placebo-controlled trial.

Abstract

BACKGROUND

The present increased incidence of atopic diseases has been associated with an altered intake of essential fatty acids (EFAs). The composition of blackcurrant seed oil (BCSO) corresponds to the recommended dietary intake of EFAs, and as a dietary supplement could, in small doses, modify the imbalance of EFAs in an efficient way.

OBJECTIVE

To assess the effect of dietary supplementation with BCSO on the prevalence of atopy at 12 months of age.

METHODS

Three hundred and thirteen pregnant mothers were randomly assigned to receive BCSO (151) or olive oil as placebo (162). The first doses were administered at 8th-16th weeks of pregnancy and were continued until the cessation of breastfeeding, followed by supplementation to the infants until the age of 2 years. Atopic dermatitis and its severity (SCORAD index) were evaluated, serum total IgE was measured and skin tests were performed at the age of 3, 12 and 24 months.

RESULTS

Parental atopy was common (81.7%) among study subjects, making them infants with increased atopy risk. There was a significantly lower prevalence of atopic dermatitis in the BCSO group than in the olive oil group at the age of 12 months (33.0% vs. 47.3%, P=0.035). SCORAD was also lower in the BCSO group than in the olive oil group at 12 months of age (P=0.035). No significant differences in the prevalence of atopic dermatitis were observed between the groups at the age of 24 months (P=0.18).

CONCLUSION

Dietary supplementation with BCSO was well tolerated and it transiently reduced the prevalence of atopic dermatitis. It could therefore be one potential tool in the prevention of atopic symptoms when used at an early stage of life. (Registration number SRCTN14869647, http://www.controlled-trials.com)

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Dermatology, University of Turku, Turku, Finland.

    , , , , , ,

    Source

    MeSH

    Dermatitis, Atopic
    Dietary Supplements
    Double-Blind Method
    Female
    Humans
    Immunoglobulin E
    Infant
    Infant, Newborn
    Linolenic Acids
    Male
    Plant Oils
    Pregnancy
    Prenatal Exposure Delayed Effects
    Skin Tests

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    20545710

    Citation

    Linnamaa, P, et al. "Blackcurrant Seed Oil for Prevention of Atopic Dermatitis in Newborns: a Randomized, Double-blind, Placebo-controlled Trial." Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 40, no. 8, 2010, pp. 1247-55.
    Linnamaa P, Savolainen J, Koulu L, et al. Blackcurrant seed oil for prevention of atopic dermatitis in newborns: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy. 2010;40(8):1247-55.
    Linnamaa, P., Savolainen, J., Koulu, L., Tuomasjukka, S., Kallio, H., Yang, B., ... Tahvonen, R. (2010). Blackcurrant seed oil for prevention of atopic dermatitis in newborns: a randomized, double-blind, placebo-controlled trial. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 40(8), pp. 1247-55. doi:10.1111/j.1365-2222.2010.03540.x.
    Linnamaa P, et al. Blackcurrant Seed Oil for Prevention of Atopic Dermatitis in Newborns: a Randomized, Double-blind, Placebo-controlled Trial. Clin Exp Allergy. 2010;40(8):1247-55. PubMed PMID: 20545710.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Blackcurrant seed oil for prevention of atopic dermatitis in newborns: a randomized, double-blind, placebo-controlled trial. AU - Linnamaa,P, AU - Savolainen,J, AU - Koulu,L, AU - Tuomasjukka,S, AU - Kallio,H, AU - Yang,B, AU - Vahlberg,T, AU - Tahvonen,R, Y1 - 2010/06/09/ PY - 2010/6/16/entrez PY - 2010/6/16/pubmed PY - 2010/11/13/medline SP - 1247 EP - 55 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin. Exp. Allergy VL - 40 IS - 8 N2 - BACKGROUND: The present increased incidence of atopic diseases has been associated with an altered intake of essential fatty acids (EFAs). The composition of blackcurrant seed oil (BCSO) corresponds to the recommended dietary intake of EFAs, and as a dietary supplement could, in small doses, modify the imbalance of EFAs in an efficient way. OBJECTIVE: To assess the effect of dietary supplementation with BCSO on the prevalence of atopy at 12 months of age. METHODS: Three hundred and thirteen pregnant mothers were randomly assigned to receive BCSO (151) or olive oil as placebo (162). The first doses were administered at 8th-16th weeks of pregnancy and were continued until the cessation of breastfeeding, followed by supplementation to the infants until the age of 2 years. Atopic dermatitis and its severity (SCORAD index) were evaluated, serum total IgE was measured and skin tests were performed at the age of 3, 12 and 24 months. RESULTS: Parental atopy was common (81.7%) among study subjects, making them infants with increased atopy risk. There was a significantly lower prevalence of atopic dermatitis in the BCSO group than in the olive oil group at the age of 12 months (33.0% vs. 47.3%, P=0.035). SCORAD was also lower in the BCSO group than in the olive oil group at 12 months of age (P=0.035). No significant differences in the prevalence of atopic dermatitis were observed between the groups at the age of 24 months (P=0.18). CONCLUSION: Dietary supplementation with BCSO was well tolerated and it transiently reduced the prevalence of atopic dermatitis. It could therefore be one potential tool in the prevention of atopic symptoms when used at an early stage of life. (Registration number SRCTN14869647, http://www.controlled-trials.com) SN - 1365-2222 UR - https://www.unboundmedicine.com/medline/citation/20545710/full_citation L2 - https://doi.org/10.1111/j.1365-2222.2010.03540.x DB - PRIME DP - Unbound Medicine ER -